Hydroxychloroquine approved to treat or prevent malaria as well as some auto-immune conditions -- does not help in the recovery of patients hospitalised due to Covid-19, but may cause harm.
Neither Remdesivir, nor hydroxychloroquine (HCQ) helps in recovery of patients hospitalised due to Covid-19, according to a new study conducted by the World Health Organization (WHO).
Patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of hydroxychloroquine, during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible Covid-19 treatment, says a new study.
The largest safety study performed on both HCQ and HCQ+AZM suggests that the combination of hydroxychloroquine (HCQ) and azithromycin (AZM) has been linked to significant cardiovascular risks, including mortality.
According to the study, HCQ+AZM had a cardiovascular mortality risk that was more than twice (2.19) as high as the comparative treatment even in the short-term based on findings from more than 3,20,000 users of that combination therapy.
Many researchers have focused on patients with systemic lupus erythematosus (SLE) and RA because HCQ is frequently taken by these patients. Anecdotal reports in the early stages of the pandemic showed these patients were not getting Covid-19.
Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients. The drug has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA's Phase 2/3 trials.
US President Donald Trump has again defended the use of hydroxychloroquine to ward off coronavirus, saying many frontline medical workers agree with him that the malaria drug works in the early stages of COVID-19 infection, despite mounting evidence that it is ineffective in treating the disease.
Hydroxychloroquine (HCQ) and chloroquine, two drugs, commonly used for the treatment of malaria, have been investigated for their potential to treat COVID-19 in more than 80 registered clinical trials, and have been shown to inhibit the novel coronavirus, SARS-COV-2 infection in cell cultures, the scientists said.
The use of hydroxychloroquine to treat coronavirus patients has become highly politicized in the US but it is used widely in India, a top White House official has said, asserting the latest research showed the malaria drug is highly effective in early stages of COVID-19.
The World Health Organization has discontinued trials of the combination HIV drugs lopinavir and ritonavir as a combined treatment for hospitalized coronavirus patients after interim results showed the drugs “produce little or no reduction in the mortality” of COVID-19 patients.
Swiss drugmaker Novartis has announced to discontinue Hydroxychloroquine (HCQ) clinical trial over acute enrollment challenges that have made completion of the trial infeasible, and not because any safety issues were reported or efficacy conclusions made.
The government on March 25 had banned the export of the drug, which was touted as a promising medicine in the treatment of COVID-19 pandemic.
Doctors can still prescribe anti-malarial drug hydroxychloroquine to patients, US Health Secretary Alex Azar said, hours after the FDA withdrew the emergency use authorisation of chloroquine and HCQ in the treatment of COVID 19 patients.
The FDA said it was no longer reasonable to believe that oral formulations of hydroxychloroquine and the related drug chloroquine may be effective in treating the respiratory illness caused by the novel coronavirus.
The Health Ministry on Saturday recommended the use of antiviral drug remdesivir in a moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.
Researchers have found that the drug hydroxychloroquine — with or without the antibiotic azithromycin — did not reduce the risk of ventilation or death, and was associated with longer length of hospital stay in COVID-19 patients.
Just as context, this development comes at a time when hydroxychloroquine has proved ineffective in the first large study which tests it in people in close contact with COVID19 infected people. These results were published this week by the New England Journal of Medicine.
The World Health Organization on Wednesday said that clinical trials of the drug hydroxychloroquine will resume, having been suspended pending a safety review in the search for coronavirus treatments.
Researchers have used an optical mapping system to demonstrate how the malaria drug hydroxychloroquine, which has been promoted as a potential treatment for COVID-19, creates serious disturbances in the electrical signals that govern heartbeat.
Top News
Latest News
